HR+/HER2- breast cancer is the most prevalent subtype of breast cancer, defined by cancer cells that possess hormone ...

A global pharmaceutical company partnered with DelveInsight to create a robust and simplified solution enabling its top executives to monitor the evolving breast cancer competitive intelligence ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...

Azenta, Inc. (Nasdaq: AZTA) today announced that Dipal Doshi, Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) ...

BURLINGTON, Mass. - Azenta, Inc. (NASDAQ: AZTA), a global provider of life sciences solutions, announced the election of ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

The colon cancer BRAFF mutation study is one of the first to be initiated under the FDA’s Project FrontRunner.

Eli Lilly & Co. (NYSE:LLY) develops, manufactures, discovers, and sells pharmaceutical products. Its products span oncology, ...